Cat. No.: HY-15354

Copy Link Print Information

TSAO-T

TSAO-T is a HIV-1 reverse transcriptase inhibitor. TSAO-T can be used in the research of HIV infection.

For research use only. We do not sell to patients.

CAS No.: 141781-17-1
Formula: C₂₄H₄₃N₃O₈SSi₂
Molecular Weight:589.85

Storage:

Please store the product under the recommended conditions in the Certificate of Analysis.

Data Sheet (273 KB)

TSAO-T Chemical Structure

CAS No.: 141781-17-1

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Use of MCE Products

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- Cellular Effect
Chemical Information
Purity & Documentation
References
Calculators
Help & FAQs
Classifications
Bioz

Biological Activity

Description

TSAO-T is a HIV-1 reverse transcriptase inhibitor. TSAO-T can be used in the research of HIV infection^[1].

All HIV Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
CCRF-CEM	CC₅₀	12 μM Compound: TSAO-T	Cytotoxicity against human CEM cells after 4 days Cytotoxicity against human CEM cells after 4 days	[PMID: 21880398]
CCRF-CEM	CC₅₀	16 μM Compound: TSAO-T	Concentration of compound required to reduce by 50% the number of viable cells in mock infected CEM cell cultures Concentration of compound required to reduce by 50% the number of viable cells in mock infected CEM cell cultures	[PMID: 15974581]
CCRF-CEM	CC₅₀	16 μM Compound: TSAO-T	Cytotoxicity against mock-infected human CEM cells assessed as reduction of cell viability after 4 days Cytotoxicity against mock-infected human CEM cells assessed as reduction of cell viability after 4 days	[PMID: 18316194]
CCRF-CEM	CC₅₀	16 μM Compound: TSAO-T	Cytotoxicity against human CEM cells Cytotoxicity against human CEM cells	[PMID: 18353641]
CCRF-CEM	EC₅₀	>10 μg/mL Compound: 7, TSAO-T	Antiviral activity against HIV1 3B harboring reverse transcriptase G190E mutant infected in human CEM cells assessed as inhibition of syncytia formation Antiviral activity against HIV1 3B harboring reverse transcriptase G190E mutant infected in human CEM cells assessed as inhibition of syncytia formation	[PMID: 21446702]
CCRF-CEM	EC₅₀	>10 μg/mL Compound: 7, TSAO-T	Antiviral activity against HIV1 3B harboring reverse transcriptase Y181I mutant infected in human CEM cells assessed as inhibition of syncytia formation Antiviral activity against HIV1 3B harboring reverse transcriptase Y181I mutant infected in human CEM cells assessed as inhibition of syncytia formation	[PMID: 21446702]
CCRF-CEM	EC₅₀	>10 μg/mL Compound: 7, TSAO-T	Antiviral activity against HIV1 3B harboring reverse transcriptase Y188L mutant infected in human CEM cells assessed as inhibition of syncytia formation Antiviral activity against HIV1 3B harboring reverse transcriptase Y188L mutant infected in human CEM cells assessed as inhibition of syncytia formation	[PMID: 21446702]
CCRF-CEM	EC₅₀	>20 μM Compound: 7, TSAO-T	Antiviral activity against wild type HIV2 infected in human CEM cells assessed as inhibition of syncytia formation Antiviral activity against wild type HIV2 infected in human CEM cells assessed as inhibition of syncytia formation	[PMID: 21446702]
CCRF-CEM	EC₅₀	>20 μM Compound: TSAO-T	Antiviral activity against HIV2 ROD infected in human CEM cells assessed as inhibition of virus-induced cytopathicity after 4 days Antiviral activity against HIV2 ROD infected in human CEM cells assessed as inhibition of virus-induced cytopathicity after 4 days	[PMID: 21880398]
CCRF-CEM	EC₅₀	>3 μg/mL Compound: 7, TSAO-T	Antiviral activity against HIV1 3B harboring reverse transcriptase E138K mutant infected in human CEM cells assessed as inhibition of syncytia formation Antiviral activity against HIV1 3B harboring reverse transcriptase E138K mutant infected in human CEM cells assessed as inhibition of syncytia formation	[PMID: 21446702]
CCRF-CEM	EC₅₀	>3.3 μg/mL Compound: 7, TSAO-T	Antiviral activity against HIV1 3B harboring reverse transcriptase Y188H mutant infected in human CEM cells assessed as inhibition of syncytia formation Antiviral activity against HIV1 3B harboring reverse transcriptase Y188H mutant infected in human CEM cells assessed as inhibition of syncytia formation	[PMID: 21446702]
CCRF-CEM	EC₅₀	>4 μM Compound: TSAO-T	Concentration of compound required to inhibit HIV-2 (ROD) induced cytopathicity in CEM cell culture by 50% Concentration of compound required to inhibit HIV-2 (ROD) induced cytopathicity in CEM cell culture by 50%	[PMID: 15974581]
CCRF-CEM	EC₅₀	>4 μM Compound: TSAO-T	Antiviral activity against HIV2 ROD in CEM cells assessed as inhibition of virus-induced cytopathogenicity after 4 days Antiviral activity against HIV2 ROD in CEM cells assessed as inhibition of virus-induced cytopathogenicity after 4 days	[PMID: 18316194]
CCRF-CEM	EC₅₀	>50 μg/mL Compound: 7, TSAO-T	Antiviral activity against HIV1 3B harboring reverse transcriptase N136A/Q/K mutant infected in human CEM cells assessed as inhibition of syncytia formation Antiviral activity against HIV1 3B harboring reverse transcriptase N136A/Q/K mutant infected in human CEM cells assessed as inhibition of syncytia formation	[PMID: 21446702]
CCRF-CEM	EC₅₀	0.01 μg/mL Compound: 7, TSAO-T	Antiviral activity against HIV1 3B harboring reverse transcriptase E138D mutant infected in human CEM cells assessed as inhibition of syncytia formation Antiviral activity against HIV1 3B harboring reverse transcriptase E138D mutant infected in human CEM cells assessed as inhibition of syncytia formation	[PMID: 21446702]
CCRF-CEM	EC₅₀	0.03 μg/mL Compound: 7, TSAO-T	Antiviral activity against wild type HIV1 3B infected in human CEM cells assessed as inhibition of syncytia formation Antiviral activity against wild type HIV1 3B infected in human CEM cells assessed as inhibition of syncytia formation	[PMID: 21446702]
CCRF-CEM	EC₅₀	0.06 μM Compound: 7, TSAO-T	Antiviral activity against wild type HIV1 infected in human CEM cells assessed as inhibition of syncytia formation Antiviral activity against wild type HIV1 infected in human CEM cells assessed as inhibition of syncytia formation	[PMID: 21446702]
CCRF-CEM	EC₅₀	0.06 μM Compound: TSAO-T	Concentration of compound required to inhibit HIV-1(IIIB) induced cytopathicity in CEM cell culture by 50% Concentration of compound required to inhibit HIV-1(IIIB) induced cytopathicity in CEM cell culture by 50%	[PMID: 15974581]
CCRF-CEM	EC₅₀	0.06 μM Compound: TSAO-T	Antiviral activity against HIV1 3B in CEM cells assessed as inhibition of virus-induced cytopathogenicity after 4 days Antiviral activity against HIV1 3B in CEM cells assessed as inhibition of virus-induced cytopathogenicity after 4 days	[PMID: 18316194]
CCRF-CEM	EC₅₀	0.06 μM Compound: TSAO-T	Antiviral activity against HIV1 3B in CEM cells assessed as inhibition of viral replication Antiviral activity against HIV1 3B in CEM cells assessed as inhibition of viral replication	[PMID: 18353641]
CCRF-CEM	EC₅₀	0.06 μM Compound: TSAO-T	Antiviral activity against HIV1 3B infected in human CEM cells assessed as inhibition of virus-induced cytopathicity after 4 days Antiviral activity against HIV1 3B infected in human CEM cells assessed as inhibition of virus-induced cytopathicity after 4 days	[PMID: 21880398]
CCRF-CEM	EC₅₀	0.07 μg/mL Compound: 7, TSAO-T	Antiviral activity against HIV1 3B harboring reverse transcriptase L100I mutant infected in human CEM cells assessed as inhibition of syncytia formation Antiviral activity against HIV1 3B harboring reverse transcriptase L100I mutant infected in human CEM cells assessed as inhibition of syncytia formation	[PMID: 21446702]
CCRF-CEM	EC₅₀	0.22 μg/mL Compound: 7, TSAO-T	Antiviral activity against HIV1 3B harboring reverse transcriptase V179N mutant infected in human CEM cells assessed as inhibition of syncytia formation Antiviral activity against HIV1 3B harboring reverse transcriptase V179N mutant infected in human CEM cells assessed as inhibition of syncytia formation	[PMID: 21446702]
CCRF-CEM	EC₅₀	0.23 μg/mL Compound: 7, TSAO-T	Antiviral activity against HIV1 3B harboring reverse transcriptase K103N mutant infected in human CEM cells assessed as inhibition of syncytia formation Antiviral activity against HIV1 3B harboring reverse transcriptase K103N mutant infected in human CEM cells assessed as inhibition of syncytia formation	[PMID: 21446702]
CCRF-CEM	EC₅₀	0.4 μM Compound: TSAO-T	Concentration of compound inhibiting Lys103-Asn mutant HIV-1(IIIB) induced cytopathicity in CEM cell culture by 50% Concentration of compound inhibiting Lys103-Asn mutant HIV-1(IIIB) induced cytopathicity in CEM cell culture by 50%	[PMID: 15974581]
CCRF-CEM	EC₅₀	1.9 μg/mL Compound: 7, TSAO-T	Antiviral activity against HIV1 3B harboring reverse transcriptase V106A mutant infected in human CEM cells assessed as inhibition of syncytia formation Antiviral activity against HIV1 3B harboring reverse transcriptase V106A mutant infected in human CEM cells assessed as inhibition of syncytia formation	[PMID: 21446702]
CCRF-CEM	EC₅₀	2 μg/mL Compound: 7, TSAO-T	Antiviral activity against HIV1 3B harboring reverse transcriptase Y181C mutant infected in human CEM cells assessed as inhibition of syncytia formation Antiviral activity against HIV1 3B harboring reverse transcriptase Y181C mutant infected in human CEM cells assessed as inhibition of syncytia formation	[PMID: 21446702]
CCRF-CEM	EC₅₀	3 μM Compound: TSAO-T	Concentration of compound inhibiting Tyr181- Cys mutant HIV-1(IIIB) induced cytopathicity in CEM cell culture by 50% Concentration of compound inhibiting Tyr181- Cys mutant HIV-1(IIIB) induced cytopathicity in CEM cell culture by 50%	[PMID: 15974581]
CCRF-CEM	EC₅₀	4.6 μM Compound: TSAO-T	Concentration of compound inhibiting Glu138-Lys mutant HIV-1(IIIB) induced cytopathicity in CEM cell culture by 50% Concentration of compound inhibiting Glu138-Lys mutant HIV-1(IIIB) induced cytopathicity in CEM cell culture by 50%	[PMID: 15974581]
Huh-7	CC₅₀	>100 μM Compound: TSAO-T	Cytotoxicity against human HuH7 cells after 72 hrs Cytotoxicity against human HuH7 cells after 72 hrs	[PMID: 21880398]
Huh-7	EC₅₀	14 μM Compound: TSAO-T	Antiviral activity against HCV2a JFH1 infected in human Huh7 cells assessed as inhibition of viral replication after 72 hrs by luciferase reporter gene assay Antiviral activity against HCV2a JFH1 infected in human Huh7 cells assessed as inhibition of viral replication after 72 hrs by luciferase reporter gene assay	[PMID: 21880398]
Lymphocyte	EC₅₀	0.034 μg/mL Compound: 12a	Concentration required to inhibit HIV-1 induced cytopathicity in human MT-4 lymphocyte cells. Concentration required to inhibit HIV-1 induced cytopathicity in human MT-4 lymphocyte cells.	[PMID: 1495006]
MT4	CC₅₀	14 μM Compound: TSAO-T	Concentration of compound required to reduce by 50% the number of viable cells in mock infected MT-4 cell cultures Concentration of compound required to reduce by 50% the number of viable cells in mock infected MT-4 cell cultures	[PMID: 15974581]
MT4	CC₅₀	14 μM Compound: TSAO-T	Inhibition of MT4 cell viability Inhibition of MT4 cell viability	[PMID: 16884295]
MT4	CC₅₀	7.7 μg/mL Compound: 12a	Concentration required to reduce human MT-4 cell viability by 50%. Concentration required to reduce human MT-4 cell viability by 50%.	[PMID: 1495006]
MT4	EC₅₀	>20 μM Compound: TSAO-T	Concentration of compound required to inhibit HIV-2 (ROD) induced cytopathicity in MT-4 cell culture by 50% Concentration of compound required to inhibit HIV-2 (ROD) induced cytopathicity in MT-4 cell culture by 50%	[PMID: 15974581]
MT4	EC₅₀	0.06 μM Compound: TSAO-T	Concentration of compound required to inhibit HIV-1(IIIB) induced cytopathicity in MT-4 cell culture by 50% Concentration of compound required to inhibit HIV-1(IIIB) induced cytopathicity in MT-4 cell culture by 50%	[PMID: 15974581]
MT4	EC₅₀	0.06 μM Compound: TSAO-T	Antiviral activity against HIV1 in MT4 cells Antiviral activity against HIV1 in MT4 cells	[PMID: 16884295]

Chemical Information

CAS No. 141781-17-1
Molecular Weight 589.85
Formula C₂₄H₄₃N₃O₈SSi₂
SMILES

O=C1NC(C(C)=CN1[C@@H]([C@@H]2O[Si](C)(C(C)(C)C)C)O[C@H](CO[Si](C)(C(C)(C)C)C)[C@@]32C(N)=CS(O3)(=O)=O)=O
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (273 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Bonache MC, et al. Improving the antiviral efficacy and selectivity of HIV-1 reverse transcriptase inhibitor TSAO-T by the introduction of functional groups at the N-3 position. J Med Chem. 2005 Oct 20;48(21):6653-60. [Content Brief]

Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Bioz

Keywords

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

TSAO-T

All HIV Isoforms